Bill

Bill > H1121


MA H1121

MA H1121
Establishing a commission to study maximum allowable costs lists


summary

Introduced
03/29/2021
In Committee
03/29/2021
Crossed Over
Passed
Dead
12/31/2022

Introduced Session

192nd General Court

Bill Summary

Relative to maximum allowable costs lists utilized by payers and pharmaceutical benefit managers to identify the maximum amount health plans will pay for certain prescription drugs. Financial Services.

AI Summary

This bill establishes a special commission to investigate the use of maximum allowable costs (MAC) lists by payers and pharmaceutical benefit managers (PBMs) to determine the maximum amount health plans will pay for certain prescription drugs. The commission will review current practices surrounding the determination and use of MAC lists, including their financial implications, industry-wide standardization, and transparency in the development and utilization processes. The commission will consist of 10 members, including representatives from the government, healthcare industry, and advocacy groups. The commission is required to submit a report with its findings and any recommended legislation within 180 days of the bill's passage.

Committee Categories

Business and Industry

Sponsors (7)

Last Action

Accompanied a study order, see H4975 (on 09/01/2022)

bill text


bill summary

Loading...

bill summary

Loading...

bill summary

Loading...